Posts by Mourabit Halima

During a recent oncology symposium, Dr. Jennifer King from Indiana University presented the results of a Phase II clinical trial (Abstract 587) evaluating cabozantinib in patients with relapsed/refractory germ-cell tumors (R/R GCT). This study explores the efficacy and safety of a multi-target tyrosine kinase inhibitor (TKI) in a patient population that has failed multiple lines of standard therapy.

In a recent academic session, Professor David F. McDermott from Beth Israel Deaconess Medical Center presented the latest findings from Part 1 of the LITESPARK-024 study. This trial evaluated the safety and preliminary efficacy of the HIF-2α inhibitor belzutifan in combination with the CDK4/6 inhibitor palbociclib in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC).

At a recent international academic conference, Professor Chad Tang from The University of Texas MD Anderson Cancer Center presented pioneering research on circulating Kidney Injury Molecule-1 (KIM-1) and circulating tumor DNA (ctDNA) as prognostic markers for oligometastatic clear cell renal cell carcinoma (ccRCC). During the session, he officially introduced the K-COMPAsS model.

At a recent international oncology academic conference, Professor Avivit Peer presented the latest findings from the KEYMAKER-U04 Substudy 04B. This study investigated the efficacy and safety of adding an anti-LAG-3 or anti-TIGIT antibody to the standard-of-care enfortumab vedotin (EV) plus pembrolizumab backbone as a first-line treatment for advanced urothelial carcinoma (UC). Our editorial team has summarized the core academic content for our readers.

With the continuous increase in the global incidence of prostate cancer and the variation in disease progression risk driven by tumor heterogeneity, accurate risk stratification is crucial for optimizing clinical treatment decisions. At a recent international oncology conference, Dr. Anna Clare Wilkins from The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust delivered a special presentation on the "External validation of a digital pathology-based multimodal artificial intelligence (MMAI) derived prognostic biomarker in the randomized phase III CHHiP trial" (Abstract 308). This study confirmed that MMAI can overcome the limitations of traditional clinicopathological models, significantly improving the predictive accuracy of survival endpoints in patients with localized prostate cancer. Our editorial team has compiled the core highlights of this presentation for our readers.

Editor’s Note: Dr. Enrique Gallardo from Parc Taulí University Hospital (Autonomous University of Barcelona) presented the final overall survival (OS) results of the phase 3 EORTC 1333/PEACE III trial (Abstract…

At the recent oncology conference, Dr. Amar Kishan, Radiation Oncologist at the University of California, Los Angeles (UCLA), presented Abstract 305, a highly anticipated individual patient data (IPD) meta-analysis addressing the optimal patient selection and duration for hormone therapy (HT) combined with post-operative radiotherapy (RT) in recurrent prostate cancer.

During a recent major international oncology congress, Professor Karim Fizazi from the University of Paris-Saclay (Gustave Roussy) presented the first results of the Phase III PEACE-2 trial. This study evaluated whether the addition of cabazitaxel and/or pelvic radiotherapy to the standard of care—androgen deprivation therapy (ADT) combined with prostate radiation—improves outcomes in patients with very high-risk localized prostate cancer.

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (GU ASCO), Dr. Martin Gleave from the University of British Columbia presented the latest data from the GUNS study (Genomic Umbrella Neoadjuvant Study). The presentation focused on the pathological responses of high-risk prostate cancer (PCa) patients with aggressive genomic alterations treated with neoadjuvant androgen receptor pathway inhibitor (ARPI) triplet versus doublet regimens.

At a recent international oncology conference, Professor Scott Tyldesley from Vancouver, Canada, delivered an oral presentation on behalf of Professor Jim Morris, sharing the 15-year long-term survival analysis of the ASCENDE-RT trial (Abstract No. 306). This study compared the long-term overall survival (OS) and prostate cancer-specific mortality (PCSM) of an external beam radiotherapy (EBRT) boost versus a low-dose-rate (LDR) brachytherapy boost in patients with localized prostate cancer. Oncology Frontier (Mediamedic) has summarized the core academic highlights to share with our readers.